Scarica l'app Stockscreener
210.39
0.18%
-0.38
Dopo l'orario di chiusura:
209.61
-0.78
-0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$210.77
Aprire:
$213.1
Volume 24 ore:
4.91M
Relative Volume:
0.72
Capitalizzazione di mercato:
$371.72B
Reddito:
$62.82B
Utile/perdita netta:
$3.60B
Rapporto P/E:
103.77
EPS:
2.0274
Flusso di cassa netto:
$19.98B
1 W Prestazione:
+4.39%
1M Prestazione:
+0.95%
6M Prestazione:
-9.46%
1 anno Prestazione:
+15.80%
Intervallo 1D:
$209.02
$214.92
Intervallo di 1 settimana:
$202.01
$214.92
Portata 52W:
$180.25
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, NVS, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
210.39 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,004.92 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.71 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc stock (US00287Y1091): earnings momentum and pipeline keep big pharma name in focus - AD HOC NEWS
AbbVie Inc. stock (US00287Y1091): Pipeline, Humira transition and US market exposure - AD HOC NEWS
ABBV Maintains Rating by Evercore ISI Group -- Price Target Lowe - GuruFocus
Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie? - The Globe and Mail
AbbVie stock (US00287Y1091): earnings beat and dividend keep focus on pipeline - AD HOC NEWS
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results? - The Globe and Mail
Mubadala Investment Co Pjsc Raises Share Stake In Abbvie, Match Group,Cuts In CVS Health - TradingView
AbbVie Stock Is Up 22% Over the Past Year. Analysts See 37% Upside to $289 Target - TIKR.com
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings - simplywall.st
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Evercore ISI Adjusts Price Target on AbbVie to $235 From $236, Maintains Outperform Rating - marketscreener.com
2 Reasons to Like ABBV and 1 to Stay Skeptical - TradingView
FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer Drug - MedCity News
BeiGene Must Face AbbVie's Chemical Trade Secret Claims - Law360
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Jim Cramer Reveals AbbVie’s (ABBV) “Good Stuff” - Insider Monkey
AbbVie stock (US00287Y1091): Business model and key drivers for US investors - AD HOC NEWS
ABBV Maintained by Piper Sandler -- Price Target Raised to $298 - GuruFocus
Piper Sandler raises Abbvie stock price target on pipeline depth By Investing.com - Investing.com Canada
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $234 - Moomoo
Piper Sandler Adjusts Price Target on AbbVie to $298 From $294, Maintains Overweight Rating - Moomoo
AbbVie stock (US00287Y1091): Q1 earnings beat and guidance raise drive 3.1% gain - AD HOC NEWS
BeiGene Can’t Toss AbbVie Trade Secrets Suit Over Cancer Therapy - Bloomberg Law News
AbbVie stock (US00287Y1091): Rises 3.3% on 2026 outlook and AGM results - AD HOC NEWS
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio - Zacks Investment Research
Goldman Sachs Large Cap Equity Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
CFO CAPITAL MANAGEMENT LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook - Yahoo Finance
AbbVie Inc. 8-K SEC Filing May 2026: Common Stock and Senior Notes Registered on NYSE - Minichart
AbbVie Inc. (ABBV) Announces Results of 2026 Annual Meeting of S - GuruFocus
AbbVie Shareholders Back Directors, Maintain Governance Structure - TipRanks
AbbVie Inc (ABBV) Stock Up 3.1% and Still Undervalued -- GF Scor - GuruFocus
[Form 4] AbbVie Inc. Insider Trading Activity - Stock Titan
[8-K] AbbVie Inc. Reports Material Event - Stock Titan
Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term - Insider Monkey
AbbVie (NYSE: ABBV) director gains 1,118-share equity award - Stock Titan
AbbVie (ABBV) director Jennifer L. Davis granted 1,118 restricted stock units as equity pay - Stock Titan
Top Stock Reports for NVIDIA, Mastercard & AbbVie - Yahoo Finance
3 reasons to buy AbbVie stock (ABBV) like there's no tomorrow - MSN
AbbVie rises 3.3% as upbeat 2026 outlook and fresh analyst optimism lift sentiment - Quiver Quantitative
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow - The Motley Fool
AbbVie’s Growth Engine Is Firing On All Cylinders (NYSE:ABBV) - Seeking Alpha
AbbVie (ABBV) Receives a Buy from Berenberg Bank - The Globe and Mail
AbbVie Stock Deserves A Higher Multiple (NYSE:ABBV) - Seeking Alpha
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
United Financial Planning Group LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs - TradingView
AbbVie shares consolidate as technicals point to continued selling pressure: weekly report - Traders Union
AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing - Seeking Alpha
AbbVie Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):